Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MoLuSpVv[3Srb36gRZN{[Xl? NGrtZlUxNjgQvF2= M2PIWlI1cA>? M4n3S4V1cGGwb3y= MorR[Y5p[W6lZYOgSW5iSyCjY3X0fYxifGmxbjDhcoQhcW6lcnXhd4V{KEWQYVOgZYJ2dmSjbnPlJIlvKHSqZTD0c5RidCClZXzsJIx6e2G2ZTDhcoQh[XRidHjlJINmdGxic4Xy[oFk\Q>? NGf3elAzPTd6N{C3PS=>
TE13 NWXzcGFNTnWwY4Tpc44hSXO|YYm= NV62R5B5OC5|zszN MUCyOIg> Mlq0eZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= MXyyOVU4QTZ4NR?=
TE13 NH3aV2VCeG:ydH;zbZMhSXO|YYm= NWnvUJJpOC5|zszN MWKyOIg> MWXpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v M1j6TVI2PTd7Nk[1
MEFs NI\jbGdHfW6ldHnvckBCe3OjeR?= NVjoTG1mPc7:TR?= MoX4NVZp NHjpTpFqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25? NUXTN2VqOjV2OEK2N|Q>
SW480  MnzkSpVv[3Srb36gRZN{[Xl? M4\2fVAvOc7:TR?= MWW0PIg> MYfEUXNQ NF3HRWNz\X[ncoPld{BGVVR? MXqyOVQ{PDl7Nx?=
PC3  NXvINXhWTnWwY4Tpc44hSXO|YYm= NIXSV3cxNjIQvF2= NVXGb4tTPDiq MkTUSG1UVw>? NXLhe4JXemW4ZYLz[ZMhTU2W MWeyOVQ{PDl7Nx?=
SW480  M17tWWZ2dmO2aX;uJGF{e2G7 NWj0fW9NOC5zzszN MV:0PIg> MoK1SG1UVw>? NU\m[3Rs[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MXWyOVQ{PDl7Nx?=
PC3  NHi2d3NHfW6ldHnvckBCe3OjeR?= NX7pZ4pROC5zzszN M3fGS|Q5cA>? NVfoO29LTE2VTx?= MUTheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? MUCyOVQ{PDl7Nx?=
SW480  NVvmVZNyTnWwY4Tpc44hSXO|YYm= M1rDZlAvOc7:TR?= NVX1OWVzPDiq NVvTR5Y{TE2VTx?= NH[5blZqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ NEP2PJgzPTR|NEm5Oy=>
PC3  NGDLVmJHfW6ldHnvckBCe3OjeR?= NIK2fooxNjIQvF2= NGPDfVk1QGh? NVnUbVU6TE2VTx?= MojCbY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? NVPB[GduOjV2M{S5PVc>
A431 MXjBdI9xfG:|aYOgRZN{[Xl? M3T3VFIwOTBxNUCvNVAxdk1? NUfrfnhkPDiq MVrEUXNQ NWj1PXgxcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4To NF3QVpEzPTN5MUC2PS=>
A431 NHzwSHdHfW6ldHnvckBCe3OjeR?= MVK1NI5O M1PMeFIwPi9zMj:yOIg> M{HKZ2ROW09? NVHYRmRv[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u M{TZWFI2OzdzME[5
MDA-MB-231 NF\6eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELsOW8xNTZyMH7N NIfPTIIzPGh? Mk\oSG1UVw>? NXi3XllTUUN3MDDv[kAyODCwTR?= Ml2wNlUyQTJ5MkG=
MCF7 M4q0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy1[VYxNTZyMH7N MmHmNlRp NVfHeZVYTE2VTx?= MUPJR|UxKG:oIEe1cm0> MYqyOVE6Ojd{MR?=
SKOV-3 MmLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\DU3M6OS1zMN88US=> MWeyOIg> MWLEUXNQ MmnpTWM2OCCxZjC1MlbPxE1? M1TvRVI2OTZ7NEmx
A549 M3X5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLZNU0yOM7:TR?= MYSyOIg> MmrWSG1UVw>? NVviVFdjUUN3MDDv[kA{NjMQvF2= MWeyOVE3QTR7MR?=
SKOV-3 NXPLdINTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfBNE4yNTIQvF2= M{DoVFQ5cA>? NYLzW5JoTE2VTx?= MYHJR|UxKG:oIECuO:69VQ>? MV6yOVE3QTR7MR?=
A549 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XYdFAvOS1zzszN NWPlTmY2PDiq MXLEUXNQ NGnQe4lKSzVyIH;mJFAvOjkQvF2= M{L6XFI2OTZ7NEmx
SKOV-3 M{HZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUewMlAyNTBwOd88US=> M1XkNlczcA>? MmTtSG1UVw>? MmfuTWM2OCCxZjCwMlMz|ryP NIfZV2gzPTF4OUS5NS=>
A549 NIPkdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[wMlAyNTBwOd88US=> MVW3Nog> NGfZTJlFVVOR M4T1UmlEPTBib3[gNE4xPs7:TR?= MYmyOVE3QTR7MR?=
HeLa M3jMVGZ2dmO2aX;uJGF{e2G7 M1eyUlI2OG6P MlPFNVZp Mn;aSG1UVw>? MXLpcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi MlyyNlUyOTZ4OEi=
CNE2 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPJ[|lzOTByLU[wNI5O MlvTNlQwPDhxN{Lo NUHtbmVscW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz MWeyOFk3QTlyMR?=
PC3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHy[IMyODBvMUCwNI5O NITaXmIzPGh? M2Ww[2lEPTBib3[gN|Axdk1? Ml3QNlQ5PTR4NUi=
LNCaP M3q3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXreZE6OTByLUGwNFBvVQ>? MWGyOIg> MXjJR|UxKG:oIEOwNI5O NWLVfW9JOjR6NUS2OVg>
HeLa  NXPSW4RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\1cpAz|ryP M3uwVFQ5cA>? MnW2[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= MY[yOFg1PjF|NR?=
HMEC-1  MmLhSpVv[3Srb36gRZN{[Xl? M2TPcVMxOG6P NFPadlczPGh? M36zXIlv[3KnYYPld{BmgHC{ZYPzbY9vKG:owrDWSWdHWjQEoH3SUmE> Ml\ONlQ4OTB4M{G=
HeLa Mki5SpVv[3Srb36gRZN{[Xl? M3nXO|FuVQ>? M{XjNlAvPWh? NHvsU5Vi[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= M3jCdFI1PzB5NEe0
ACP02 NGXjbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnXU5Q2OjVyL{O1NE82ODCwTR?= NYrON|lxOjSq MljC[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NELYSlIzPDZ4OEW0Oy=>
ACP03 M3zHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\ES3MzPTBxM{WwM|UxOG6P MXKyOIg> MmGw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? NHPhfHYzPDZ4OEW0Oy=>
U87 GBM M4K2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTw[4RsOTByL{OwNE82ODBibl2= NHn2SlA4OiCq MXmxNFAmKGW2aHHuc4w> MVHy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= Mme5NlQ1PjR6NEG=
U87 GBM MkTtSpVv[3Srb36gRZN{[Xl? MljHNVAxNzVyMDDOcS=> MVO0PEBp Mn\MNVAxLSCndHjhco9t MWnJcoR2[2W|IGPlcoV{[2WwY3WtUIls\SCDbITldoF1cW:wczDpckBPfWOuZXHyJG1wenCqb3zv[5k> MmX5NlQ1PjR6NEG=
RPE MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHwWWYxNjJxMD60M|AvQC9zIN88US=> MkXBNlQwPDhxN{KgbC=> MlGwSG1UVw>? MmLwbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gZpkh[2WubDDjfYNt\SCjcoLld5Q> NEj5N40zPDR3Nk[wNi=>
HT29  MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7sNVgxKG6P MUe3NkBp MonjTWM2OCCxZjCxPFAhdk1? MWGyOFM3QDJ4NR?=
hMSCs MUTGeY5kfGmxbjDBd5NigQ>? MnLYOk4zPSCwTR?= NEPobZgzPCCq M3:3OmROW09? NXHONIxXe3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> NH;ESmczPDNzMkO1Oi=>
Huh7  M4e5[2Z2dmO2aX;uJGF{e2G7 Ml7UNE4yNzBwNT:xMlAh|ryP NWL0RZZLOjSq M2T0WZN2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NV\hcoViOjR{Nkm2O|I>
SKOV3 M4DzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFKzVmgxNjB3LUKg{txO NWTwRVE2OTBxMkSvOFghcA>? M{Dlb2ROW09? M4PuXo1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MkXzNlQzOjN6MEG=
A2780 M1TUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nNPVAvODVvMjFOwG0> MUOxNE8zPC92ODDo M3H6OWROW09? MoPtcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M2DSWFI1OjJ|OECx
SRA01/04  MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWT5R|dzOC5{IN88US=> M2SzPFQ5KGh? M{TyWGROW09? NX\Pcohve3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? NFy1NFMzPDF3N{i3PC=>
HLEB3 M4PDSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHENE4zKM7:TR?= NEnjfJo1QCCq M{SzNGROW09? MYLzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> M1vacVI1OTV5OEe4
SRA01/04  NHO1dHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2wTVExNjRxMD64JO69VQ>? M4jLPVQ5KGh? MkTQSG1UVw>? M3vXNolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M{nGfFI1OTV5OEe4
HLEB3 NGjudHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOwMlQwOC56IN88US=> M{jGR|Q5KGh? NYTle3pJTE2VTx?= MW\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MVeyOFE2Pzh5OB?=
HCT116 M{\tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;o[ZhUOC5{IN88US=> NXzN[nhoOTJiaB?= NY\wZ2xb\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBz[WSrYYTpc44> NFS1bZczPDF{MkKzNS=>
CA46 M4e4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\FPXRkOy94L{GyM|I1NzR6IH7N M2DEOFQ5KGh? MnPvbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>? MkDaNlQxPjR7NUG=
PMNs M3;BXWZ2dmO2aX;uJGF{e2G7 NV23TVdbOzBibl2= MWC0PEBp MYPpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= MoruNlM6QDh4MUe=
H1299 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HaR|HDqM7:TdMg M1y4cVI1NzR6L{eyJIg> NGPiXlRmfGijbn;s MV;pcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> MVmyN|kyPjZyOR?=
A549 NXjGWGJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKwMlI2NzBwNT:xJO69VQ>? MkTCNlQwPDhxN{KgbC=> NIiyW3JmfGijbn;s MVXpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NFjxelIzOzh4N{m5NS=>
H1299 NXPJbo9MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXTNE4zPS9yLkWvNUDPxE1? NEHPVIYzPC92OD:3NkBp NWPFWWZD\XSqYX7vcC=> NFPufYxqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MVSyN|g3Pzl7MR?=
A549 NH\yVmVCeG:ydH;zbZMhSXO|YYm= MVKwMlUwOSEQvF2= NF;M[IQ1QCCq MnPO[ZRp[W6xbB?= M4D2folv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUWyN|g3Pzl7MR?=
H1299 NETP[pdCeG:ydH;zbZMhSXO|YYm= M{O2[FAvPS9zIN88US=> M2TKcFQ5KGh? NUK0V3VV\XSqYX7vcC=> NYrXUGlPcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3v4UlI{QDZ5OUmx
SUM149PT MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLx[GhYOi95LkWvNVAh|ryP NV;oeJliPDhiaB?= NIj6cpRFVVOR Ml7wbY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? MY[yN|c6OjZ|OB?=
SUM190PT M17KZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfLVJY2OC9zMECvNlUxKG6P M4LISFQ5KGh? MVfEUXNQ MWLpcoR2[2W|IHPlcIwh\GWjdHigZZQhPTBibl2gd4Vve2m2aY\lcJk> NHXncmYzOzd7Mk[zPC=>
HCT1 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUewMlIwOS5yL{WuNEDPxE1? NWXiSmtZOTJxMkSvN|YwPDhiaB?= NF7oUXVqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NXTNOHZvOjN5N{CwNFA>
Lovo MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWqwMlIwOS5yL{WuNEDPxE1? MnfHNVIwOjRxM{[vOFghcA>? MY\pcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NI\QW4wzOzd5MECwNC=>
AGS MnS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCwMlAyPS1zIN88US=> NI[5RWM4OiCq MkLDbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MnLzNlM4PDVyMkS=
Huh7 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:0[ZhoOSEQvF2= M3HvSVI1KGh? MmDMSG1UVw>? Mm[ydoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> MkHaNlM3PDN7M{O=
ECC1 NVzaTHFWTnWwY4Tpc44hSXO|YYm= MVu1NFAhdk1? MkDjOUBl NYPNeoo6TE2VTx?= NInSSZZqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MnXNNlM2OzB5Nkm=
HEC1A MnHDSpVv[3Srb36gRZN{[Xl? M{e5dFUxOCCwTR?= MnjFOUBl Mkj4SG1UVw>? M{POfIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NVvxdmF4OjN3M{C3Olk>
EN1 M37hWWZ2dmO2aX;uJGF{e2G7 NGWzOVk2ODBibl2= NUn5Opl3PSCm M2nCbGROW09? NWD1ZXlNcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NF3WTXEzOzV|MEe2PS=>
MFE296 NH3n[W5HfW6ldHnvckBCe3OjeR?= MmTVOVAxKG6P MnHkOUBl NH[wVWtFVVOR Mk\rbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NYf4U|lROjN3M{C3Olk>
HASMCs NGTZ[nRHfW6ldHnvckBCe3OjeR?= NYnBWWRtOC13MECgcm0> M{PJTVYh\A>? NIHkS3Nld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? NGLjPXEzOzVzOES2Oy=>
U373 NFr0eIJHfW6ldHnvckBCe3OjeR?= NUPwPGh4OC5{NT:wMlUwOSEQvF2= Ml3PNlQhcA>? NGDjU2JqdmO{ZXHz[ZMhWFJvQjDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFVCgmGmQx?= NU\zR5E6OjN2N{SxO|E>
ARN8  MWPGeY5kfGmxbjDBd5NigQ>? M1KzelAvODVvMjFOwG0> M{DVTVI1KGh? MmTTdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> MlT3NlM1PzB3NEC=
MCF7 MnrHSpVv[3Srb36gRZN{[Xl? M37sZVAvODVvMjFOwG0> NFzwO2UzPCCq M{LWO5Jm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ Mnn3NlM1PzB3NEC=
H1299  NIfkXWJHfW6ldHnvckBCe3OjeR?= M2TsbFAvOzQkgKOxxsDDvU1? MkX0NlQwPDhiaB?= NWL0SYdlTE2VTx?= M1;WNIlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= MnjLNlM1PjF7N{W=
H1299 NYHL[41mTnWwY4Tpc44hSXO|YYm= NX;xXmJoOC53IN88US=> Mlv2OFghcA>? NGHnN25FVVOR NUXLd5RZcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? NVXPZ|Z[OjN2NkG5O|U>
H1299 NYLINlVLTnWwY4Tpc44hSXO|YYm= NHy1cmoxNjVizszN MkLzOFghcA>? MV7EUXNQ NUXB[3pUcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= NWG0[WZxOjN2NkG5O|U>
MG-63  M3q2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjzS5ExNjNizszN NGDwZoYyOi17NjDo Mm\KSG1UVw>? NYTkO2JFcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> M1rBU|I{PDVzOEG3
LM8 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjsNE4{KM7:TR?= M13pdVEzNTl4IHi= MYrEUXNQ MkjFbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MVmyN|Q2OThzNx?=
K562 NXTSRoV6TnWwY4Tpc44hSXO|YYm= MlXiNE42KM7:TR?= MU[yOEBp MWLleIhidm:u NXz1cYh1\GWlcnXhd4V{KHSqZTDlcpp6dWViYXP0bZZqfHlib3[gTGRCS3NiY3:teJJm[XSvZX70JJdqfGhiY4XyZ5VucW5? NVHKZnpiOjN2M{C5OVc>
HEL MkLxSpVv[3Srb36gRZN{[Xl? NGTM[XgxNjVizszN M{TlVlI1KGh? Ml7i[ZRp[W6xbB?= MWXk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M1jVW|I{PDNyOUW3
HL60 MXnBdI9xfG:|aYOgRZN{[Xl? NV;LWpp3OSEQvF2= M3XIdVI1KGh? M2TkRolv\HWlZYRCpINmdGxiZHXheIg> M2LTeFI{PDByNUG5
KG1 M3PDTGFxd3C2b4Ppd{BCe3OjeR?= M13WWlEh|ryP M3TQNlI1KGh? M1jWSYlv\HWlZYRCpINmdGxiZHXheIg> M4f5WlI{PDByNUG5
Kazumi M3jK[GFxd3C2b4Ppd{BCe3OjeR?= NFi5OpcyKM7:TR?= NH3GSVgzPCCq MVTpcoR2[2W|wrDj[YxtKGSnYYTo NIPrVokzOzRyMEWxPS=>
K562 NXKwW5BDSXCxcITvd4l{KEG|c3H5 NX;EUmZwOSEQvF2= MV[yOEBp NHjMRYhqdmS3Y3XzxsBk\WyuIHTlZZRp MmfpNlM1ODB3MUm=
THP1 MnfxRZBweHSxc3nzJGF{e2G7 M4nlOVEh|ryP M3TSN|I1KGh? NFvpWllqdmS3Y3XzxsBk\WyuIHTlZZRp M{C2ZlI{PDByNUG5
SH-SY5Y NEO3[IxHfW6ldHnvckBCe3OjeR?= MnnFNlUxKG6P NEnnWpEyPiCq MoHxZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= MXmyN|MzPjR{Mh?=
HEK293 MmnHSpVv[3Srb36gRZN{[Xl? M{nvdlEhyrWPwrC= MmLSNVghcMLi NXjHVZJDcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= MoDBNlMzQDR6NEi=
HTK NYnrdIcxTnWwY4Tpc44hSXO|YYm= M1LC[VQxOCCwTR?= M2nPdVczKGh? NYr1XJA{cW6qaXLpeJMhXEeILd8y5qCUUW6mdXPl[EBOgW:oaXLyc4Jt[XO2IFTp[oZmemWwdHnheIlwdg>? NYfhRXJ[OjN{OESwNFI>
HTK M4f5cWZ2dmO2aX;uJGF{e2G7 MWixNFAuQDBybl2= MkHTO|IhcA>? M1rm[YJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w MmXJNlMzQDRyMEK=
Caco-2  MnSxSpVv[3Srb36gRZN{[Xl? M2rreFEhyrWPwrC= MlPvNlQhcA>? NFTvOpVl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= NWPofJZxOjNzOUWwO|A>
HeLa NH;SOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPOVHkyODBibl2= MX:yOEBp Ml62SG1UVw>? MWrJR|UxKG:oIEGwNI5O M1;USFI{OTZ3N{S4
HeLa NH;HXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPVOFAhdk1? M1vtWFQ5KGh? NEWxV|lFVVOR NXnaUHp{UUN3MDDv[kA1OG6P NFKw[nMzOzF4NUe0PC=>
HeLa MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTlNlAhdk1? M{DOZ|czKGh? NIPFbo9FVVOR MVrJR|UxKG:oIEKwcm0> NHL0V|MzOzF4NUe0PC=>
HeLa NX7WfoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fwXlExNzNyL{WwJI5O Ml\qO|IhcA>? MXTEUXNQ M3XlcYlv[3KnYYPld{B1cGViboXtZoVzKG:oIF3NVEAp|pUQqH2pJIxwe3NiY3XscJMh\G:|ZTDk[ZBmdmSnboTsfS=> NVjNS5gyOjNzNkW3OFg>
MDA-MB-231 NUnrV|lPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi1T2UzPS12MECgcm0> NGnYNlk1QCCq MXPJR|UxKG:oIEK2N{4zdk4EoB?= Ml3NNlMxPTVzOUi=
MCF-7  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjqNlUuPDByIH7N MoWyOFghcA>? NGrqNY5KSzVyIH;mJFIzOC52bl2= MkTGNlMxPTVzOUi=
ECC-1  MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;nSoN2OTByIH7N NYTwTWdxOjRiaB?= Ml3D[ZRp[W6xbB?= MmPkbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn M2TRRlI{ODJ6OECz
HEC-1A MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\GW3V[OTByIH7N MmPXNlQhcA>? NEK2OpJmfGijbn;s NUfGRXBmcW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml MmLINlMxOjh6MEO=
NHAC-kn MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNE8yODBxNUCwJI5O MX[xNkBp MmKxSG1UVw>? NHntSI5KSzVyIH;mJFUxOG6P NF;hPIkzOzBzN{i3NS=>
A549 NHHUfnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XuVFI2OCCwTR?= M1TxfVYuPzJiaB?= NFzIWJdFVVOR MYTjZZV{\XNiYTDndoVifGW{IHnubIljcXSxcomg[YZn\WO2IHPvcYJqdmVid3n0bEBVYFRib4Kg[ZJtd3Srbnni M2fGdFIzQTl2N{iw
MG-63 NGPLV5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH3VWRyOzByIH7N NH7DdIgyOiCq MXvEUXNQ NYHYTlkycW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= MV6yNlc6QTN|OB?=
MG-63 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuN|AxKG6P NUHvOpB3OjRiaB?= NUKzb49nTE2VTx?= NVX2PFdlcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= MVWyNlc6QTN|OB?=
MG-63 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrEenY{ODBibl2= M{jZOVQ5KGh? NH\3W5pFVVOR Mk\xbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? MmrtNlI4QTl|M{i=
HL60  MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWwSnUyPTBvM{WwJI5O MlTmNlQhcA>? Mo\pbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> M1Ht[|IzPzV|N{O5
U937 M4G2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LyN|E2OC1|NUCgcm0> M{nITlI1KGh? M3jXUolv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> MoXZNlI4PTN5M{m=
SCC-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqyNFAuOzJyMDDuUS=> NYT6VXRKOTJxMkSvOFghcA>? M{niO2ROW09? MVfpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NVTz[HZwOjJ3NUKzNlE>
U87  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixNFAuOzByIH7n MV:yOEBp M4f3TolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A4OiViIHH0JFIxOG6p MWOyNlI4ODh2OR?=
K562 M2\ySWZ2dmO2aX;uJGF{e2G7 NIH5V4EyKM7:TR?= MUWxNkBp NIH1d|hFVVOR NVTYVnZz\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NF7YXVEzOjF5OUG5PC=>
Reh MmPiSpVv[3Srb36gRZN{[Xl? NHj4b2MxNjNxMTFOwG0> MX[xNkBp NIWzOHVFVVOR M1;JdoVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS M1jxe|IzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID